BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18556884)

  • 61. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
    Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
    Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cancer. A risky business--assessing breast cancer risk.
    Levy-Lahad E; Plon SE
    Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
    [No Abstract]   [Full Text] [Related]  

  • 63. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
    Suthers GK
    ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hereditary breast cancer and genetic counseling in young women.
    Brunet J
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():7-9. PubMed ID: 20711663
    [No Abstract]   [Full Text] [Related]  

  • 66. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
    Woodward AM; Davis TA; Silva AG; Kirk JA; Leary JA;
    J Med Genet; 2005 May; 42(5):e31. PubMed ID: 15863663
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Genetic testing by cancer site: ovary.
    Weissman SM; Weiss SM; Newlin AC
    Cancer J; 2012; 18(4):320-7. PubMed ID: 22846732
    [TBL] [Abstract][Full Text] [Related]  

  • 70. BRCA testing: ethics lessons for the new genetics.
    Sherwin S
    Clin Invest Med; 2004 Feb; 27(1):19-22. PubMed ID: 15061582
    [No Abstract]   [Full Text] [Related]  

  • 71. Should I Be Tested for BRCA Mutations?
    Jin J
    JAMA; 2019 Aug; 322(7):702. PubMed ID: 31429898
    [No Abstract]   [Full Text] [Related]  

  • 72. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
    Foretova L; Machackova E; Navratilova M; Pavlu H; Hruba M; Lukesova M; Valik D
    Hum Mutat; 2004 Apr; 23(4):397-8. PubMed ID: 15024741
    [TBL] [Abstract][Full Text] [Related]  

  • 73. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy.
    Stuppia L; Di Fulvio P; Aceto G; Pintor S; Veschi S; Gatta V; Colosimo A; Cianchetti E; Cama A; Mariani-Costantini R; Battista P; Palka G
    Hum Mutat; 2003 Aug; 22(2):178-9. PubMed ID: 12872265
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 75. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Meta-analysis of BRCA1 and BRCA2 penetrance.
    Chen S; Parmigiani G
    J Clin Oncol; 2007 Apr; 25(11):1329-33. PubMed ID: 17416853
    [TBL] [Abstract][Full Text] [Related]  

  • 77. BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
    Printz C
    Cancer; 2016 Apr; 122(8):1149. PubMed ID: 27061519
    [No Abstract]   [Full Text] [Related]  

  • 78. Cancer genetics or cancer genomics in the era of genomic medicine?
    Daly PA
    Ann Oncol; 2003; 14 Suppl 3():iii19-25. PubMed ID: 12821534
    [No Abstract]   [Full Text] [Related]  

  • 79. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Genetic counselling for hereditary predisposition to ovarian and breast cancer.
    Mackay J; Szecsei CM
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii334-8. PubMed ID: 20943638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.